LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity

Journal of Chemical Neuroanatomy

Volumn 76, Issue , 2016, Pages 90-97

  Karuppagounder, Senthilkumar S ^a,d   Xiong, Yulan ^a,d,e   Lee, Yunjong ^a,d,f   Lawless, Maeve C ^a,c,d   Kim, Donghyun ^a   Nordquist, Emily ^a,b   Martin, Ian ^a,d,g   Ge, Preston ^a,b   Brahmachari, Saurav ^a,d   Jhaldiyal, Aanishaa ^a,d   Kumar, Manoj ^a,d   Andrabi, Shaida A ^a,d   Dawson, Ted M ^a,d   Dawson, Valina L ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

^d ADRIENNE HELIS MALVIN MEDICAL RESEARCH FOUNDATION   (United States)

^e KANSAS STATE UNIVERSITY   (United States)

^f Sungkyunkwan University School of Medicine   (South Korea)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Dopamine; Environmental factor; Genetic factor; LRRK2; MPTP; Parkinson's Disease; Stereology

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; LEUCINE RICH REPEAT KINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; COMPARATIVE STUDY; DOPAMINERGIC NERVE CELL; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; MALE; MOUSE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; STEREOMETRY; TRANSGENIC MOUSE;

EID: 84960158144     PISSN: 08910618     EISSN: 18736300     Source Type: Journal    
DOI: 10.1016/j.jchemneu.2016.01.007     Document Type: Article

References (42)

1. Andres-Mateos, E., Mejias, R., Sasaki, M., Li, X., Lin, B.M., Biskup, S., Zhang, L., Banerjee, R., Thomas, B., Yang, L., Liu, G., Beal, M.F., Huso, D.L., Dawson, T.M., Dawson, V.L., Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). J. Neurosci. 29 (2009), 15846–15850.
2. Blesa, J., Przedborski, S., Parkinson's disease: animal models and dopaminergic cell vulnerability. Front. Neuroanat., 8, 2014, 155.
3. Blesa, J., Phani, S., Jackson-Lewis, V., Przedborski, S., Classic and new animal models of Parkinson's disease. J. Biomed. Biotechnol., 2012, 2012, 845618.
4. Chung, K.K., Dawson, V.L., Dawson, T.M., New insights into Parkinson's disease. J. Neurol. 250:Suppl. 3 (2003), III15–24.
5. Cooper, O., Seo, H., Andrabi, S., Guardia-Laguarta, C., Graziotto, J., Sundberg, M., McLean, J.R., Carrillo-Reid, L., Xie, Z., Osborn, T., Hargus, G., Deleidi, M., Lawson, T., Bogetofte, H., Perez-Torres, E., Clark, L., Moskowitz, C., Mazzulli, J., Chen, L., Volpicelli-Daley, L., Romero, N., Jiang, H., Uitti, R.J., Huang, Z., Opala, G., Scarffe, L.A., Dawson, V.L., Klein, C., Feng, J., Ross, O.A., Trojanowski, J.Q., Lee, V.M., Marder, K., Surmeier, D.J., Wszolek, Z.K., Przedborski, S., Krainc, D., Dawson, T.M., Isacson, O., Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci. Transl. Med., 4, 2012, 141ra190.
6. Dauer, W., Kholodilov, N., Vila, M., Trillat, A.C., Goodchild, R., Larsen, K.E., Staal, R., Tieu, K., Schmitz, Y., Yuan, C.A., Rocha, M., Jackson-Lewis, V., Hersch, S., Sulzer, D., Przedborski, S., Burke, R., Hen, R., Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 14524–14529.
7. Dawson, T.M., Ko, H.S., Dawson, V.L., Genetic animal models of Parkinson's disease. Neuron 66 (2010), 646–661.
8. Demoulin, J.B., Montano-Almendras, C.P., Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis. Am. J. Blood Res. 2 (2012), 44–56.
9. Di Monte, D.A., Wu, E.Y., Langston, J.W., Role of astrocytes in MPTP metabolism and toxicity. Ann. N. Y. Acad. Sci 648 (1992), 219–228.
10. Di Monte, D.A., Lavasani, M., Manning-Bog, A.B., Environmental factors in Parkinson's disease. Neurotoxicology 23 (2002), 487–502.
11. Jackson-Lewis, V., Przedborski, S., Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2 (2007), 141–151.
12. Karl, T., Pabst, R., von Horsten, S., Behavioral phenotyping of mice in pharmacological and toxicological research. Exp. Toxicol. Pathol. 55 (2003), 69–83.
13. Karuppagounder, S.S., Ahuja, M., Buabeid, M., Parameshwaran, K., Abdel-Rehman, E., Suppiramaniam, V., Dhanasekaran, M., Investigate the chronic neurotoxic effects of diquat. Neurochem. Res. 37 (2012), 1102–1111.
14. Karuppagounder, S.S., Brahmachari, S., Lee, Y., Dawson, V.L., Dawson, T.M., Ko, H.S., The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. Sci. Rep., 4, 2014, 4874.
15. Lane, E.L., Winkler, C., Brundin, P., Cenci, M.A., The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiol. Dis. 22 (2006), 334–345.
16. Langston, J.W., Forno, L.S., Rebert, C.S., Irwin, I., Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res. 292 (1984), 390–394.
17. Lees, A.J., Hardy, J., Revesz, T., Parkinson's disease. Lancet 373 (2009), 2055–2066.
18. Martin, I., Dawson, V.L., Dawson, T.M., Recent advances in the genetics of Parkinson's disease. Annu. Rev. Genom. Hum. Genet. 12 (2011), 301–325.
19. Martin, I., Abalde-Atristain, L., Kim, J.W., Dawson, T.M., Dawson, V.L., Abberant protein synthesis in G2019S LRRK2 Drosophila Parkinson disease-related phenotypes. Fly (Austin) 8 (2014), 165–169.
20. Martin, I., Kim, J.W., Dawson, V.L., Dawson, T.M., LRRK2 pathobiology in Parkinson's disease. J. Neurochem. 131 (2014), 554–565.
21. Martin, I., Kim, J.W., Lee, B.D., Kang, H.C., Xu, J.C., Jia, H., Stankowski, J., Kim, M.S., Zhong, J., Kumar, M., Andrabi, S.A., Xiong, Y., Dickson, D.W., Wszolek, Z.K., Pandey, A., Dawson, T.M., Dawson, V.L., Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease. Cell 157 (2014), 472–485.
22. Mattson, M.P., Chan, S.L., Duan, W., Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. Physiol. Rev. 82 (2002), 637–672.
23. Moehle, M.S., Daher, J.P., Hull, T.D., Boddu, R., Abdelmotilib, H.A., Mobley, J., Kannarkat, G.T., Tansey, M.G., West, A.B., The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins. Hum. Mol. Genet. 24 (2015), 4250–4267.
24. Morelli, P.I., Martinsson, S., Ostergren-Lunden, G., Friden, V., Moses, J., Bondjers, G., Krettek, A., Lustig, F., IFNgamma regulates PDGF-receptor alpha expression in macrophages, THP-1 cells, and arterial smooth muscle cells. Atherosclerosis 184 (2006), 39–47.
25. Ng, C.H., Mok, S.Z., Koh, C., Ouyang, X., Fivaz, M.L., Tan, E.K., Dawson, V.L., Dawson, T.M., Yu, F., Lim, K.L., Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J. Neurosci. 29 (2009), 11257–11262.
26. Rajput, A., Dickson, D.W., Robinson, C.A., Ross, O.A., Dachsel, J.C., Lincoln, S.J., Cobb, S.A., Rajput, M.L., Farrer, M.J., Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67 (2006), 1506–1508.
27. Ramonet, D., Daher, J.P., Lin, B.M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L., Liu, Y., Swing, D.A., Beal, M.F., Troncoso, J.C., McCaffery, J.M., Jenkins, N.A., Copeland, N.G., Galter, D., Thomas, B., Lee, M.K., Dawson, T.M., Dawson, V.L., Moore, D.J., Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One, 6, 2011, e18568.
28. Ray, A., Martinez, B.A., Berkowitz, L.A., Caldwell, G.A., Caldwell, K.A., Mitochondrial dysfunction, oxidative stress, and neurodegeneration elicited by a bacterial metabolite in a C. elegans Parkinson's model. Cell Death Dis., 5, 2014, e984.
29. Saha, S., Guillily, M.D., Ferree, A., Lanceta, J., Chan, D., Ghosh, J., Hsu, C.H., Segal, L., Raghavan, K., Matsumoto, K., Hisamoto, N., Kuwahara, T., Iwatsubo, T., Moore, L., Goldstein, L., Cookson, M., Wolozin, B., LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J. Neurosci. 29 (2009), 9210–9218.
30. Sanders, L.H., Laganiere, J., Cooper, O., Mak, S.K., Vu, B.J., Huang, Y.A., Paschon, D.E., Vangipuram, M., Sundararajan, R., Urnov, F.D., Langston, J.W., Gregory, P.D., Zhang, H.S., Greenamyre, J.T., Isacson, O., Schule, B., LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction. Neurobiol. Dis. 62 (2014), 381–386.
31. Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A., Tomiyama, H., Nakashima, K., Hasegawa, K., Obata, F., Yoshikawa, T., Kawakami, H., Sakoda, S., Yamamoto, M., Hattori, N., Murata, M., Nakamura, Y., Toda, T., Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41 (2009), 1303–1307.
32. Savitt, J.M., Dawson, V.L., Dawson, T.M., Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest. 116 (2006), 1744–1754.
33. Schmitz, C., Hof, P.R., Recommendations for straightforward and rigorous methods of counting neurons based on a computer simulation approach. J. Chem. Neuroanat. 20 (2000), 93–114.
34. Schmitz, C., Hof, P.R., Design-based stereology in neuroscience. Neuroscience 130 (2005), 813–831.
35. Smith, W.W., Pei, Z., Jiang, H., Dawson, V.L., Dawson, T.M., Ross, C.A., Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9 (2006), 1231–1233.
36. Veldman, B.A., Wijn, A.M., Knoers, N., Praamstra, P., Horstink, M.W., Genetic and environmental risk factors in Parkinson's disease. Clin. Neurol. Neurosurg. 100 (1998), 15–26.
37. West, A.B., Moore, D.J., Biskup, S., Bugayenko, A., Smith, W.W., Ross, C.A., Dawson, V.L., Dawson, T.M., Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 16842–16847.
38. West, A.B., Moore, D.J., Choi, C., Andrabi, S.A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K.L., Dawson, V.L., Dawson, T.M., Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16 (2007), 223–232.
39. Xiong, Y., Coombes, C.E., Kilaru, A., Li, X., Gitler, A.D., Bowers, W.J., Dawson, V.L., Dawson, T.M., Moore, D.J., GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet., 6, 2010, e1000902.
40. Xiong, Y., Yuan, C., Chen, R., Dawson, T.M., Dawson, V.L., ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2. J. Neurosci. 32 (2012), 3877–3886.
41. Yue, M., Hinkle, K.M., Davies, P., Trushina, E., Fiesel, F.C., Christenson, T.A., Schroeder, A.S., Zhang, L., Bowles, E., Behrouz, B., Lincoln, S.J., Beevers, J.E., Milnerwood, A.J., Kurti, A., McLean, P.J., Fryer, J.D., Springer, W., Dickson, D.W., Farrer, M.J., Melrose, H.L., Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol. Dis. 78 (2015), 172–195.
42. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B., Stoessl, A.J., Pfeiffer, R.F., Patenge, N., Carbajal, I.C., Vieregge, P., Asmus, F., Muller-Myhsok, B., Dickson, D.W., Meitinger, T., Strom, T.M., Wszolek, Z.K., Gasser, T., Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004), 601–607.